Results 111 to 120 of about 9,424 (215)

SGLT1 and SGLT2 inhibition, circulating metabolites, and cerebral small vessel disease: a mediation Mendelian Randomization study

open access: yesCardiovascular Diabetology
Background Sodium-glucose cotransporter 2 (SGLT2) and SGLT1 inhibitors may have additional beneficial metabolic effects on circulating metabolites beyond glucose regulation, which could contribute to a reduction in the burden of cerebral small vessel ...
Yanchen Lv, Xin Cheng, Qiang Dong
doaj   +1 more source

Molecular mechanisms and computational insights into human SGLTs: advancing toward selective SGLT1 inhibition

open access: yesFrontiers in Molecular Biosciences
The sodium and glucose transporters (SGLTs) are integral membrane proteins crucial for glucose homeostasis, with SGLT1 and SGLT2 being widely studied as primary therapeutic targets.
Nadhiri Kaijage, Sebastian Kraszewski
doaj   +1 more source

The primer sequences used for amplification of SGLT1, SGLT2, SGLT3a, and SGLT3b.

open access: yes, 2013
The primer sequences used for amplification of SGLT1, SGLT2, SGLT3a, and SGLT3b.
Xin J. Zhou (305431)   +6 more
core   +1 more source

XBP1-mediated transcriptional regulation of SLC5A1 in human epithelial cells in disease conditions

open access: yesCell & Bioscience
Background Sodium-Glucose cotransporter 1 and 2 (SGLT1/2) belong to the family of glucose transporters, encoded by SLC5A1 and SLC5A2, respectively. SGLT2 is almost exclusively expressed in the renal proximal convoluted tubule cells. SGLT1 is expressed in
Yifei Sun   +8 more
doaj   +1 more source

Knockout of NA\u3csup\u3e+\u3c/sup\u3e-Glucose Cotransporter SGLT1 Mitigates Diabetes-Induced Upregulation of Nitric Oxide Synthase NOS1 in the Macula Densa and Glomerular Hyperfiltration

open access: yes, 2019
Na+-glucose cotransporter (SGLT)1 mediates glucose reabsorption in late proximal tubules. SGLT1 also mediates macula densa (MD) sensing of an increase in luminal glucose, which increases nitric oxide (NO) synthase 1 (MD-NOS1)-mediated NO formation and ...
Koepsell, Hermann   +11 more
core   +1 more source

10 Pre-clinical studies of sotagliflozin in hypertrophic cardiomyopathy

open access: yesJournal of Clinical and Translational Science
OBJECTIVES/GOALS: Study the regulatory role of sodium glucose co-transporter 1 (SGLT1) in cardiomyocytes and the therapeutic potential of sotagliflozin in hypertrophic cardiomyopathy (HCM) by (a) quantifying SGLT1 expression in HCM and (b) examining the ...
Rebecca Taichman   +3 more
doaj   +1 more source

‐glucose cotransporter SGLT1 from humans and rabbit

open access: yes, 2001
Udgivelsesdato: 2001-Mar-151. In order to study its role in steady state water transport, the Na+-glucose cotransporter (SGLT1) was expressed in Xenopus laevis oocytes; both the human and the rabbit clones were tested.
Wright, E M   +9 more
core   +1 more source

Die Dynamik des Natrium-D-Glukose Co-Transporters SGLT1 in Säugetierzelllinien

open access: yes, 2005
Die Verteilung des Na\(^{+}\)/Glukosetransporter SGLT1 wurde mit Hilfe immunzytochemischer Methoden analysiert. Dabei wurde SGLT1 sowohl in der Plasmamembran als auch in mikrotubuli-assoziierten Endosomen detektiert. Die intrazelluläre Bewegung von SGLT1
Scharlau, Daniel
core   +1 more source

Xinbao Pill ameliorates heart failure via regulating the SGLT1/AMPK/PPARα axis to improve myocardial fatty acid energy metabolism

open access: yesChinese Medicine
Background Heart failure (HF) is characterized by a disorder of cardiomyocyte energy metabolism. Xinbao Pill (XBW), a traditional Chinese medicine formulation integrating “Liushen Pill” and “Shenfu Decoction,” has been approved by China Food and Drug ...
Linjie Pan   +9 more
doaj   +1 more source

SGLT1 staining in lung tissues.

open access: yes, 2019
Alveolar structures in lung from Sham (A to D), CLP saline (CLP-sal, E to H), CLP salbutamol (CLP-salb, I to L) and CLP phlorizin (CLP-phlo, M to P) treated rats. Sections (A, E, I and M) were immunostained with anti-F-actin antibody (red).
Douglas Carvalho Caixeta (4048033)   +13 more
core   +1 more source

Home - About - Disclaimer - Privacy